**Product Name**: Relugolix  
**Catalog Number**: T3630  
**CAS Number**: 737789-87-6  
**Molecular Formula**: C29H27F2N7O5S  
**Molecular Weight**: 623.63  
**Appearance**: Solid

**Description**: Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation.

**Storage**: 2 years -80°C in solvent; 3 years -20°C powder;

<table>
<thead>
<tr>
<th>Solubility</th>
<th>DMSO</th>
<th>55 mg/mL (88.2 mM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(&lt; 1 mg/mL refers to the product slightly soluble or insoluble)</td>
<td></td>
</tr>
</tbody>
</table>

| Receptor (IC50) | GNRHR |

**Reference**
1. MacLean DB et al. J Clin Endocrinol Metab. 2015 Dec;100(12):4579-87.  

**FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**

Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, please follow the storage recommendations on the product data sheet.